Welcome to the GARDASIL Access ProgramThe GARDASIL Access Program is currently undergoing a strategic evaluation that may result in changes to application requirements. Therefore, the Program is not accepting new applications at the present time. Please visit the site again in June 2012 for a Program update. Thank you in advance for your cooperation.
Through the GARDASIL Access Program, Merck & Co., Inc. (Whitehouse Station, NJ, USA) has pledged to donate at least 3 million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] for use in approved projects in eligible lowest income countries throughout the world.
The GARDASIL Access Program enables organizations and institutions in eligible lowest income countries to gain operational experience designing and implementing smaller scale human papillomavirus (HPV) vaccination projects, with the goal of supporting the development of successful child and adolescent immunization models. Click here for more information on the GARDASIL Access Program.
To date, 980,800 doses of GARDASIL have shipped to 22 participants in 20 countries, enough to vaccinate more than 326,500 eligible girls. Click here to learn more about the participating organizations and institutions that have completed or are currently implementing HPV vaccination projects supported by the GARDASIL Access Program.
|
|
